{"id": "1356648280248229889", "creation": 1612285129.0, "user_id": "1247376635004936192", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 0, "quote_count": 0}}, "text": "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost #COVID19 #vaccine: an interim analysis of a randomised controlled phase 3 trial in #Russia\n\nThis interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91.6% efficacy.\nhttps://t.co/tMwuIMCjWP https://t.co/Mu96i9hpht", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#RUSSIA"]}